Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
After finishing at $5.07 in the prior trading day, Candel Therapeutics Inc (NASDAQ: CADL) closed at $5.02, down -0.99%. In other words, the price has decreased by -$0.99 from its previous closing price. On the day, 0.57 million shares were traded. CADL stock price reached its highest trading level at $5.13 during the session, while it also had its lowest trading level at $4.97.
Ratios:
Our goal is to gain a better understanding of CADL by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.04 and its Current Ratio is at 7.04. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Stephens on October 28, 2025, initiated with a Overweight rating and assigned the stock a target price of $15.
On September 03, 2025, BofA Securities Downgraded its rating to Neutral which previously was Buy but kept the price unchanged to $7.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jul 28 ’25 when Nichols William Garrett sold 937 shares for $6.98 per share. The transaction valued at 6,540 led to the insider holds 52,493 shares of the business.
Nichols William Garrett sold 781 shares of CADL for $3,936 on Jun 30 ’25. The Chief Medical Officer now owns 52,493 shares after completing the transaction at $5.04 per share. On Jun 30 ’25, another insider, WILLIAM GARRETT NICHOLS, who serves as the Officer of the company, bought 3,593 shares for $4.90 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CADL now has a Market Capitalization of 275573408 and an Enterprise Value of 183227392.
Stock Price History:
The Beta on a monthly basis for CADL is -0.92, which has changed by 0.18181813 over the last 52 weeks, in comparison to a change of 0.14151978 over the same period for the S&P500. Over the past 52 weeks, CADL has reached a high of $14.60, while it has fallen to a 52-week low of $3.79. The 50-Day Moving Average of the stock is -5.91%, while the 200-Day Moving Average is calculated to be -17.75%.
Shares Statistics:
The stock has traded on average 757.69K shares per day over the past 3-months and 621560 shares per day over the last 10 days, according to various share statistics. A total of 54.89M shares are outstanding, with a floating share count of 41.06M. Insiders hold about 25.21% of the company’s shares, while institutions hold 38.13% stake in the company. Shares short for CADL as of 1761868800 were 7479907 with a Short Ratio of 9.86, compared to 1759190400 on 7222409. Therefore, it implies a Short% of Shares Outstanding of 7479907 and a Short% of Float of 17.21.
Earnings Estimates
Investors are keenly observing as 2 analysts analyze and rate. The current performance of Candel Therapeutics Inc (CADL) in the stock market.The consensus estimate for the next quarter is -$0.28, with high estimates of -$0.23 and low estimates of -$0.33.
Analysts are recommending an EPS of between -$0.77 and -$0.77 for the fiscal current year, implying an average EPS of -$0.77. EPS for the following year is -$0.46, with 1.0 analysts recommending between -$0.46 and -$0.46.
